UK votes to stay in the EMA post-Brex­it

7 years ago
Pharma

Cel­lec­tar climbs (then sinks) on PhII DL­B­CL da­ta; Vyr­i­ad inks deal with Pfiz­er/Mer­ck KGaA

7 years ago
News Briefing

Armed with $36M A round, Johns Hop­kins spin­out Neu­raly heads to PhI Parkin­son's tri­al

7 years ago
Financing
Startups

J&J joins block­buster HIV com­bo race with new­ly ap­proved 4-in-1 pill

7 years ago
Pharma

By the num­bers: Se­ries A rounds are bust­ing out, plat­forms are in, M&A is down, val­u­a­tions surge and 2018 looks ...

7 years ago
Financing
Deals

Eli Lil­ly, Pfiz­er cel­e­brate a PhI­II suc­cess for their block­buster pain drug con­tender tanezum­ab -- but ques­tions ...

7 years ago
R&D

No­var­tis CEO Vas Narasimhan hits the brakes on US drug price hikes -- right af­ter tap­ping the gas

7 years ago
Pharma

Boom time: Ru­bius, Cri­net­ics find big sup­port in up­sized IPOs to­tal­ing $343M raise

7 years ago
Financing
Startups

An­ti­fun­gal out, can­cer in: Rev­o­lu­tion scores $500M Sanofi deal on first on­col­o­gy pro­gram

7 years ago
Pharma

Pre-rev­enue vac­cine de­vel­op­er CanSi­no lines up at a buzzing HKEX

7 years ago
Financing
China

6 Di­men­sions backs Lyv­gen's $30M B round; No­var­tis hands off glob­al rights to IL-2 drug

7 years ago
News Briefing

On its way to mak­ing Hong Kong his­to­ry, As­cle­tis eyes $457M haul in GIC-backed IPO

7 years ago
Financing
China

Vivek Ra­maswamy strikes again, this time launch­ing a Bei­jing-based biotech play­er with a pipeline

7 years ago
Startups

The next Nim­bus? Head of bil­lion-dol­lar drug pro­gram launch­es HotSpot with $45M A round

7 years ago
Financing
Startups

Fast-grow­ing As­cen­t­age has big plans for its lat­est $150M raise -- but what about the IPO?

7 years ago
Financing
China

Roche hands over an­oth­er batch of pos­i­tive PhI­II da­ta on its new flu drug, look­ing for an ear­ly-win­ter launch

7 years ago
R&D

J&J de­clares a his­toric suc­cess as In­vokana comes through in PhI­II chron­ic kid­ney dis­ease tri­al

7 years ago
R&D

An­oth­er stark warn­ing over CRISPR/Cas9’s po­ten­tial to do last­ing harm dents share prices

7 years ago
Pharma

FDA ex­perts back GSK's new malar­ia drug; Sang­amo's new­ly mint­ed CTO jumps to biotech up­start

7 years ago
News Briefing

Phar­ma 'greed' emerges as a po­tent po­lit­i­cal is­sue in a rau­cous elec­tion year

7 years ago
Pharma

Tak­ing on biode­fense threats, an­tibi­otics mak­er Spero inks $54M in gov­ern­ment deals

7 years ago
R&D
Pharma

Chas­ing Bio­gen, the Pli­ant crew banks a $62M round to fu­el their shot at fi­bro­sis tar­gets

7 years ago
Financing

Guard­ing against a night­mare sce­nario, FDA ap­proves new drug to counter small­pox out­break

7 years ago
Pharma

Back­ers of Tes­la and SpaceX fund 29-year-old Al­ice Zhang's AI-pow­ered neu­ro­science start­up

7 years ago
Financing
Startups
First page Previous page 1025102610271028102910301031 Next page Last page
A service from the Financial Times